June 1st Week, 2025 Regulatory Events 🎯 Takeda and Pfizer’s brentuximab vedotin (Adcetris; CD30 ADC) + ECADD chemo regimen has been approved by the European commission for the Tx of adult patients with newly diagnosed stage IIb with risk factors/III/IV Hodgkin lymphoma. (Ref 1) ❓ Can brentuximab-based regimen be the standard of care? What are its strengths and limitations? 🎯 Tempest Therapeutics’ amezalpat (selective PPAR⍺ antagonist) has been granted an Orphan Drug Desi

April 4th Week, 2025 Regulatory & Market News 🎯 Akeso Biopharma’s penpulimab-kcqx (anti-PD-1) + chemo received the US FDA approval for the Tx of previously untreated recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (nkNPC). 👉 The FDA also approved single agent penpulimab-kcqx for the Tx of nkNPC patients who have progressed following platinum chemo and at least one other prior line of therapy. (Ref 1) ❓ How does this approval affect the current Tx landscape